EPCAM and breast cancer: Survival was estimated to be worse in patients with higher expression EpCAM in breast cancer tissue [39], especially in the luminal B HER2 positive and basal-like breast cancer [42,43], and ovarian [44], prostate [45], and gall bladder cancers [46].